Literature DB >> 19287557

Adult ADHD pharmacotherapy.

.   

Abstract

Entities:  

Year:  2008        PMID： 19287557      PMCID： PMC2644467          DOI： 10.4088/pcc.v10n0608

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN： 1523-5998


× No keyword cloud information.
  10 in total

1.  A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.

Authors:  Joseph Biederman; Eric Mick; Craig Surman; Robert Doyle; Paul Hammerness; Theresa Harpold; Stephanie Dunkel; Meghan Dougherty; Megan Aleardi; Thomas Spencer
Journal:  Biol Psychiatry       Date:  2005-12-20       Impact factor: 13.382

2.  Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial.

Authors:  Richard H Weisler; Joseph Biederman; Thomas J Spencer; Timothy E Wilens; Stephen V Faraone; Allan K Chrisman; Stephanie C Read; Simon J Tulloch
Journal:  CNS Spectr       Date:  2006-08       Impact factor: 3.790

3.  A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder.

Authors:  Thomas Spencer; Joseph Biederman; Timothy Wilens; Robert Doyle; Craig Surman; Jefferson Prince; Eric Mick; Megan Aleardi; Kathleen Herzig; Stephen Faraone
Journal:  Biol Psychiatry       Date:  2005-03-01       Impact factor: 13.382

4.  Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder.

Authors:  T Spencer; J Biederman; T Wilens; S Faraone; J Prince; K Gerard; R Doyle; A Parekh; J Kagan; S K Bearman
Journal:  Arch Gen Psychiatry       Date:  2001-08

5.  Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.

Authors:  Thomas J Spencer; Lenard A Adler; James J McGough; Rafael Muniz; Hai Jiang; Linda Pestreich
Journal:  Biol Psychiatry       Date:  2006-11-29       Impact factor: 13.382

6.  Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms.

Authors:  Steven A Safren; Michael W Otto; Susan Sprich; Carol L Winett; Timothy E Wilens; Joseph Biederman
Journal:  Behav Res Ther       Date:  2005-07

7.  Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies.

Authors:  David Michelson; Lenard Adler; Thomas Spencer; Frederick W Reimherr; Scott A West; Albert J Allen; Douglas Kelsey; Joachim Wernicke; Anthony Dietrich; Denái Milton
Journal:  Biol Psychiatry       Date:  2003-01-15       Impact factor: 13.382

8.  PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate.

Authors:  Thomas J Spencer; Joseph Biederman; Patrick E Ciccone; Bertha K Madras; Darin D Dougherty; Ali A Bonab; Elijahu Livni; Dolly A Parasrampuria; Alan J Fischman
Journal:  Am J Psychiatry       Date:  2006-03       Impact factor: 18.112

9.  Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.

Authors:  Lenard A Adler; David W Goodman; Scott H Kollins; Richard H Weisler; Suma Krishnan; Yuxin Zhang; Joseph Biederman
Journal:  J Clin Psychiatry       Date:  2008-09-09       Impact factor: 4.384

10.  A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults.

Authors:  Stephen V Faraone; Joseph Biederman; Timothy E Wilens; Joel Adamson
Journal:  Psychol Med       Date:  2007-03-12       Impact factor: 7.723
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.